EDIT
Price
$2.59
Change
+$0.08 (+3.19%)
Updated
Sep 29 closing price
Capitalization
385.49M
40 days until earnings call
Intraday BUY SELL Signals
IMTX
Price
$8.56
Change
+$0.06 (+0.71%)
Updated
Sep 29 closing price
Capitalization
1.29B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs IMTX

EDIT vs IMTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. IMTX commentary
Sep 30, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Buy and IMTX is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
EDIT vs IMTX: Fundamental Ratings
EDIT
IMTX
OUTLOOK RATING
1..100
725
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
7962
P/E GROWTH RATING
1..100
10051
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for IMTX (78) in the null industry. This means that EDIT’s stock grew somewhat faster than IMTX’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IMTX (100) in the null industry. This means that EDIT’s stock grew similarly to IMTX’s over the last 12 months.

IMTX's SMR Rating (98) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that IMTX’s stock grew similarly to EDIT’s over the last 12 months.

IMTX's Price Growth Rating (62) in the null industry is in the same range as EDIT (79) in the Biotechnology industry. This means that IMTX’s stock grew similarly to EDIT’s over the last 12 months.

IMTX's P/E Growth Rating (51) in the null industry is somewhat better than the same rating for EDIT (100) in the Biotechnology industry. This means that IMTX’s stock grew somewhat faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITIMTX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
COMPARISON
Comparison
Sep 30, 2026
Stock price -- (EDIT: $2.59 vs. IMTX: $8.56)
Brand notoriety: EDIT and IMTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 55% vs. IMTX: 98%
Market capitalization -- EDIT: $385.49M vs. IMTX: $1.29B
EDIT [@Biotechnology] is valued at $385.49M. IMTX’s [@Biotechnology] market capitalization is $1.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green while IMTX’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • IMTX’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than IMTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while IMTX’s TA Score has 3 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 6 bearish.
  • IMTX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both EDIT and IMTX are a bad buy in the short-term.

Price Growth

EDIT (@Biotechnology) experienced а -11.30% price change this week, while IMTX (@Biotechnology) price change was -3.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.40%. For the same industry, the average monthly price growth was -11.74%, and the average quarterly price growth was +0.75%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

IMTX is expected to report earnings on Nov 17, 2026.

Industries' Descriptions

@Biotechnology (-6.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
IMTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HCKT9.870.09
+0.92%
Hackett Group
MAR361.623.05
+0.85%
Marriott International
RADX1.52N/A
N/A
Radiopharm Theranostics Limited
AVO13.07-0.03
-0.23%
Mission Produce
ASB28.68-0.28
-0.97%
Associated Banc-Corp

IMTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with SLDB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMTX
1D Price
Change %
IMTX100%
+0.71%
SLDB - IMTX
51%
Loosely correlated
-1.65%
VIR - IMTX
49%
Loosely correlated
+1.33%
ABEO - IMTX
47%
Loosely correlated
-2.46%
EDIT - IMTX
47%
Loosely correlated
+3.19%
KURA - IMTX
45%
Loosely correlated
+1.84%
More